News
The day at a glance · 3 min read
Mood · Mixed
+15
Sentiment, −100 to +100
LLY Dividend Growth (5Y)
15.23%
GILD Dividend Yield
2.50%
BMY Dividend Yield
4.25%
Key driverStrong clinical trial results from Eli Lilly offset by expanded legal risks at Johnson & Johnson and major portfolio rebalancing at Berkshire
Daily briefHealthcare· Money365.Market AI ·

Lilly Obesity Drug Succeeds; JNJ Talc Verdict Expands

Retatrutide clears Phase 3 trial while Johnson & Johnson faces fresh talc liability; Berkshire exits UnitedHealth stake

Big Pharma & Biotech

Bullish
LLYGILDBMY
Eli Lilly and Company ($LLY) reported that its experimental obesity drug, retatrutide, cleared a major late-stage clinical trial, according to a CNBC report published on May 21. The company maintains a 5-year dividend growth rate of 15.23%.
Gilead Sciences ($GILD) received an upgrade to 'Buy' from Maxim, with the company carrying an annual dividend yield of 2.50%. At the RBC Capital Markets conference, Gilead's Chief Medical Officer Dietmar Berger outlined upcoming clinical and regulatory priorities across oncology, inflammation and HIV, with a focus on advancing Trodelvy lung data and the long-acting HIV pipeline.
Bristol-Myers Squibb ($BMY) announced on May 20 that it was partnering with Anthropic to deploy AI capabilities, while maintaining an annual dividend yield of 4.25%.

JNJ Stock Price

$234.34
JNJ
Johnson & Johnson ($JNJ) was found liable in a Minnesota cosmetic talc mesothelioma lawsuit, sharing responsibility with other manufacturers. The jury verdict resulted in a significant personal injury award for the plaintiff, expanding the scope of talc related legal exposure for the company. This case adds to Johnson & Johnson's ongoing talc litigation and raises fresh questions about future legal and reputational risk. The company is currently trading at around $234.34 per share.

Health Insurance & Managed Care

Neutral

UNH Dividend Yield

2.31%
UNH
UnitedHealth Group Incorporated ($UNH) carries an annual dividend yield of 2.31% and operates through two distinct businesses: its insurance wing, UnitedHealthcare, and its health services segment, Optum. Berkshire Hathaway unveiled a wide-ranging portfolio overhaul in its latest 13F filing, with CEO Greg Abel overseeing full exits from several major positions including UnitedHealth. These moves reflect the biggest shift in Berkshire's capital allocation approach in decades, with a clearer tilt toward technology and AI focused investments away from traditional healthcare holdings.

MedTech & Devices

Neutral

STXS Implied Upside

124.7%

STXS Price Target

$3.5-$0.5
STXS
Stereotaxis, Inc. ($STXS) is trading with an implied upside of 124.7% and an RSI of 39.6, emerging as a notable oversold play in the AI sector. Piper Sandler lowered its price target on $STXS to $3.5 from $4.0 on May 13, 2026, while keeping an 'Overweight' rating. The medtech company continues to attract analyst attention despite the revised price target.

Looking Ahead

Neutral
LLYJNJGILDUNH
The healthcare sector faces a mixed outlook as positive clinical trial results for obesity treatments contrast with expanding legal liabilities and major institutional portfolio shifts. Gilead's focus on Trodelvy lung data and long-acting HIV pipeline developments will be key catalysts to monitor. The rebalancing of major portfolios away from traditional managed care positions toward technology and AI-focused healthcare investments signals a potential shift in sector leadership. Johnson & Johnson's expanding talc litigation exposure remains a significant overhang on the diversified healthcare giant.

Important Disclaimer — Not Investment Advice

Disclaimer: This article is provided by Money365.Market for general information and educational purposes only. It is not financial advice, a personal recommendation, or an inducement to buy, sell, or invest in any security or product. Capital is at risk and the value of investments can go down as well as up; past performance does not indicate future results. You should seek independent advice from an FCA-authorised adviser before making any financial decision.

Read the full disclaimer — 8 further points, including total-loss risk, our regulatory status and conflicts of interest

Nothing here is an offer or a solicitation to buy or sell anything, and reading it creates no advisory or fiduciary relationship between you and Money365.Market. Any decision you take is your own.

  • You can lose money — including all of it. Individual companies can and do fail, and some of the assets discussed can fall to zero. Only commit money you can afford to lose, and never borrow to invest on the strength of anything you read here.
  • Forecasts are opinion, not fact. Any valuation model, scenario, fair-value range, estimate or other forward-looking statement is illustrative, rests on assumptions that may prove wrong, and is never a price target, a forecast of actual outcomes, or a promise of any return.
  • Published at a point in time. Figures were believed accurate on the publication or last-updated date shown above and are not maintained afterwards; we are under no obligation to update them. Market and company data comes from third-party sources and is provided without warranty of accuracy, completeness or timeliness.
  • Automated content. This brief was compiled by an automated pipeline from validated news and market-data sources and passed through editorial and compliance checks. Automated content can still contain errors — verify anything you intend to rely on.
  • We are not regulated. Money365.Market is not authorised or regulated by the UK Financial Conduct Authority, is not registered with the U.S. Securities and Exchange Commission or FINRA as an investment adviser or broker-dealer, and is not a tax adviser. We hold no licence to give personal financial advice and do not do so.
  • Interests and independence. Money365.Market is not affiliated with, endorsed by or sponsored by any company, fund, exchange or platform mentioned, and is not paid to feature them. The author may hold positions in securities or assets discussed. The site earns revenue from advertising, subscriptions and, where labelled, affiliate links; this does not influence what we publish.
  • Your jurisdiction matters. Tax treatment, contribution limits, product availability and investor protections differ by country and can change. Speak to a qualified tax professional for tax matters, and to a locally licensed adviser if you are outside the UK.

Full terms: Disclaimer · Terms of Service · Privacy Policy